Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-27T14:13:11.412Z Has data issue: false hasContentIssue false
  • English
  • Français

Drug-Induced Parkinsonism and Other Movement Disorders

Published online by Cambridge University Press:  18 September 2015

R.T. Ross
R.T. Ross*
Affiliation:
Section of Neurology, Department of Medicine, University of Manitoba, Winnipeg
*
Section of Neurology, PE-126, 820 Sherbrook Street, Winnipeg, Manitoba, Canada R3A LR9
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

This is a review of reserpine, haloperidol, and various phenothiazines that produce parkinsonism and other movement disorders. The by-products of illicit meperidine synthesis, MPTP and its more sinister companion, MPP, are also discussed. Movement disorders, transient or fixed, frank parkinsonism and/or dyskinesia, due to a variety of other medications and toxic agents are included. These are methanol, lithium, methyldopa, antimetabolites, antidepressants, sympathomimetic anorexiants, some types of antihistamines, and various combinations of agricultural chemicals.

Résumé:

RÉSUMÉ:

Nous revoyons la réserpine, l'halopéridol et différentes phénothiazines qui provoquent le parkinsonisme et d'autres anomalies du mouvement. Nous discutons également de dérivés de la synthèse illégale de la mépéridine, le MPTP et son compagnon encore plus sinistre, le MPP. Nous incluons les anomalies du mouvement, qu'elles soient passagères ou fixes, le parkinsonisme franc et/ou les dyskinésies, dus à une variété d'autres médicaments et agents toxiques. Ces agents toxiques sont le méthanol, le lithium, le méthyldopa, les antimétabolites, les antidépresseurs, les anorexiants sympathicomimétiques, certains types d'antihistaminiques et différentes combinaisons de produits chimiques agricoles.

Type
Special Features and Reviews
Information
Canadian Journal of Neurological Sciences , Volume 17 , Issue 2 , May 1990 , pp. 155 - 162
Copyright
Copyright © Canadian Neurological Sciences Federation 1990

References

REFERENCES

1. Langstem, JW, Ballard, PA. Chronic parkinsonism in humans due to a meperidine-analog synthesis. Science 1983; 219: 979–980.CrossRefGoogle Scholar
2. Ballard, PA, Tetrud, JW, Langston, JE. Permanent human parkinsonism due to l-methyl-4-4 phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neurology 1985; 35: 949–956.CrossRefGoogle Scholar
3. Calne, DB. Progress in Parkinson’s disease. N Engl J Med 1984; 310: 523–524.CrossRefGoogle ScholarPubMed
4. Snyder, SH. Parkinson’s disease: clues to aetiology from a toxin. Nature 1984; 311: 514.CrossRefGoogle ScholarPubMed
5. Rajput, AH, Offord, KP, Beard, CM, et al. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol 1984; 16: 278–282.CrossRefGoogle Scholar
6. Eldridge, R, Rocca, WA. The clinical syndrome of striatal dopamine deficiency: parkinsonism induced by MPTP. N Engl J Med 1985; 313: 1159–1160.Google ScholarPubMed
7. Duvoisin, RC, Schweitzer, MD. Paralysis agitans mortality in England and Wales 1885–1962. Br J Prev Soc Med 1966; 20: 27–33.Google Scholar
8. Kurland, LT. Epidemiology: incidence, geographic distribution, and genetic considerations. In: Fields, WS, ed. Pathogenesis and Treatment of Parkinsonism. Springfield, Illinois: Charles C. Thomas, 1958; 5–49.Google Scholar
9. Calne, S, Schoenberg, B, Martin, W, et al. Familial Parkinson’s disease: possible role of environmental factors. Can J Neurol Sei 1987; 14: 303–305.CrossRefGoogle ScholarPubMed
10. Golbe, LI, Duvoisin, RC, Miller, DC. A large kindred with autosomal dominant Parkinson’s disease. Ann Neurol 1988; 24: 151–152.Google Scholar
11. Marguilies, ME. Parkinsonism and brain tumor. Arch Neurol Psychiat 1953; 70: 112–113.Google Scholar
12. Carlsson, A, Lundquist, M, Magnusson, T. 3,4 Dihydroxy- phenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957; 180: 1200.CrossRefGoogle Scholar
13. Gordon, JH, Koller, WC. Animal models used to evaluate potential antiparkinson drugs. In: Koller, WC, ed. Handbook of Parkinson’s Disease. New York: Marcel Dekker Inc. 1987; 288–289.Google Scholar
14. Janssen, PAJ, Jageneau, AH. A new series of potent analgesics. J Pharm Pharmacol 1965; 10(1): 14–21.CrossRefGoogle Scholar
15. LaVerne, A. Compendium of neuropsychopharmacology. J Neuropsychiat 1961; 2: 280–286.Google Scholar
16. Stimmel, GL. Tardive dyskinesia with low-dose, short-term, neuroleptic therapy. Am J Hosp Pharm 1976; 33: 961–963.Google ScholarPubMed
17. Gerlach, J, Simmelsgaard H. Tardive dyskinesia during and following treatment with haloperidol, haloperidol+biperidin, thioridazine, and clozapine. Psychopharmacology (Berlin) 1978; 59: 105–112.Google Scholar
18. Anderson, BG, Reker, D, Cooper, TB. Prolonged adverse effects of haloperidol in normal subjects. Letter. N Engl J Med 1981; 305: 643–644.Google Scholar
19. Gelenberg, AJ, Mandel, MR. Catatonic reactions to high potency neuroleptic drugs. Arch Gen Psychiat 1977; 34: 947–950.CrossRefGoogle ScholarPubMed
20. Flaherty, JA, Lahmeyer, HW. Laryngeal-pharyngeal dystonia as a possible cause of asphyxia with haloperidol treatment. Am J Psychiatry 1978; 135: 1414–1415.Google Scholar
21. Ellenhorn, MJ, Barcelous, DG. Medical Toxicology. New York: Elsevier 1988.Google Scholar
22. Corsini, GU, Del Zompo, M, Spissu, A, et al. Parkinsonism by haloperidol and piribedil. Psychopharmacology 1978; 59: 139–141.CrossRefGoogle ScholarPubMed
23. Chase, TN, Woods, AC, Glaubiger, GA. Parkinson disease treated with a suspected dopamine receptor agonist. Arch Neurol 1974; 30: 383–386.CrossRefGoogle Scholar
24. Carlsson, A. Receptor-mediated control of dopamine metabolism. In: Usdin, E, Bunney, WE, eds. Pre- and postsynaptic receptors. New York: Marcel Dekker 1975; 49.Google Scholar
25. Bunney, BS, Aghajanian, GK. Evidence for drug actions on both pre- and postsynaptic catecholamine receptors in the CNS. In: Usdin, E and Bunney, WE, eds. Pre- and postsynaptic receptors. New York: Marcel Dekker 1975; 122.Google Scholar
26. Steck, H. Le syndrome extra-pyramidal et diencephalique au cours des traitments au forgactil au serpasil. Ann Med Psychol 1954; 1: 737–743.Google Scholar
27. Seeman, P. The membrane actions of anesthetics and tranquilizers. Pharmacol Rev 1972; 24: 583–655.Google ScholarPubMed
28. Spector, S, Gordon, R, Sjoerdsma, A, et al. End-product inhibition of tyrosine hydroxylase as a possible mechanism for regulation of norephinephrine synthesis. Mol Pharmacol 1967; 3: 549–555.Google Scholar
29. Javoy, F, Agid, Y, Bouvet, D, et al. Feedback control of dopamine synthesis in dopaminergic terminals of the rat striatum. J Pharmacol ExpTher 1972; 192: 454–463.Google Scholar
30. Matthysee, S. Antipsychotic drug actions: a clue to the neuropathology of schizophrenia. Fed Proc 1973; 32: 200–205.Google Scholar
31. Famebo, LO, Hamberger, B. Drug-induced changes in the release of 3monoamines from field stimulated rat brain slices. Acta Physiol Scand 1971; 371 (Suppl): 35–44.Google Scholar
32. Kruse, W. Development of parkinsonism after gradual reduction of fluphenazine dosage. Am J Psychiatry 1963; 119: 995–996.CrossRefGoogle ScholarPubMed
33. Seeman, P, Staiman, A, Lee, T, et al. The membrane actions of tranquilizers in relation to neuroleptic-induced parkinsonism and tardive dyskinesia. In: Forrest, IS, Carr, CJ, Usdin, E, eds. The Phenothiazines and Structurally Related Drugs. New York: Raven Press 1974; 137–148.Google Scholar
34. Crowley, TJ, Rutledge, CO, Hohen, MM, et al. Low urinary dopamine and prediction of phenothiazine induced parkinsonism: a preliminary report. Am J Psychiatry 1976; 133: 703–706.Google ScholarPubMed
35. Cahan, RB, Parish, DD. Reversibility of drug-induced parkinsonism. Am J Psychiatry 1960; 116: 1022–1023.CrossRefGoogle ScholarPubMed
36. Stratas, NE, Phillips, RD, Walker, PA, et al. A study of drug-induced parkinsonism. Diseases of the Nervous System 1963; 24: 180.Google ScholarPubMed
37. Duvoisin, RC. Problems in the treatment of parkinsonism. Adv Exp Med Biol 1977; 90: 131–155.CrossRefGoogle ScholarPubMed
38. Rajput, AH, Rozdilsky, B, Hronykiewicz, O, et al. Reversible drug-induced parkinsonism. Arch Neurol 1982; 39: 644–646.CrossRefGoogle ScholarPubMed
39. Wilson, JA, Primrose, WR. Drug-induced parkinsonism. (Letter) Br Med J 1986; 293: 957.CrossRefGoogle ScholarPubMed
40. Stephen, PJ, Williamson, J. Drug-induced parkinsonism in the elderly. Lancet 1984; 2: 1082–1083.CrossRefGoogle ScholarPubMed
42. Delay, J, Deniker, P, Thuillier, J. Similitude des accidents nerveux de la prochorperazine avec certains troubles post-encephalitiques. Ann Med Psychol 1957; 115(3): 506–510.Google Scholar
43. Marie, P, Levy, G. Le syndrome excito-moteur de l’encephalite epidemique, ses principales manifestations; choree rhythmee, brachycinesis et myoclonies parkinsonnisme. Rev Neurol (Paris) 1920; 27: 513–516.Google Scholar
44. Marie, P, Levy, G. Deux nouveaux cas de movements involuntaries post-encephalitiques: a localisation exclusivement lingulo-facio masticatrice. Bull et mem Soc med d hop de Par 1920; 3.S., 44: 546–552.Google Scholar
45. Marie, P, Levy, G. Un nouveau cas de localisation facio-mastica-trice du syndrome excito-moteur tardif de l’encephalite epidemique avec manifestations de tic douloureux de la face. Bull et mem Soc med d hop de Par 1920; 3.S., 44: 661–664.Google Scholar
46. Hunter, R, Earl, CJ, Thornicroft, S. An apparently irreversible syndrome of abnormal movements following phenothiazine medication. Proc Roy Soc Med 1964; 57: 758–762.CrossRefGoogle ScholarPubMed
47. Klawans, HL, Bergen, D, Bruyn, GW. Prolonged drug-induced parkinsonism. Confin Neurol 1973; 35: 368–377.CrossRefGoogle ScholarPubMed
48. Hirschberg, E. Long persisting drug-induced parkinsonism — a case report. Pharmacopsychiatry 1987; 20: 278.CrossRefGoogle ScholarPubMed
49. Schwab, RS, England, AC. Parkinson syndromes due to various specific causes. In: Vinkenpt, , Bruyn, GW, eds. Handbook of Clinical Neurology, Vol. 6. Diseases of the Basal Ganglia. New York, Wiley 1968; 227–247.Google Scholar
50. Demars, JPCA. Neuromuscular effects of long term phenothiazine medication, ECT, and leucotomy. J Nerv Ment Dis 1966; 143: 170–176.CrossRefGoogle Scholar
51. Murdoch, PS, Williamson, J. A danger in making the diagnosis of Parkinson’s disease. Lancet 1982; 1: 1212–1213.CrossRefGoogle ScholarPubMed
52. Crane, GE. Parkinsonism and tardive dyskinesia. (Letter) Am J Psychiatry 1978; 135: 619.CrossRefGoogle ScholarPubMed
53. Edelstein, H, Knight, RT. Severe parkinsonism in two AIDS patients taking prochlorperazine. (Letter) Lancet 1987; 2: 341–342.CrossRefGoogle ScholarPubMed
54. Nath, A, Jankovic, J, Pettigrew, LC. Movement disorders and AIDS. Neurology 1987; 37: 37–41.CrossRefGoogle ScholarPubMed
55. Davis, GC, Williams, AC, Markey, SP, et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1979; 1: 249–254.CrossRefGoogle ScholarPubMed
56. Langston, JW,Ballard, P, Tetrud, JW, et al. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979–980.CrossRefGoogle ScholarPubMed
57. Langston, JW, Ballard, PA. Parkinson’s disease in a chemist working with l-methyl-4-phenyl-l,2,5,6-tetrahydropyridine. (Letter) N Engl J Med 1983; 309: 310.Google Scholar
58. Heikkila, RE, Manzino, L, Cabbat, FS, et al. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6,-tetrahydropyridine by monamine oxidase inhibitors. Nature 1984, 311: 467–469.CrossRefGoogle Scholar
59. Markey, SP, Johannessen, JN, Chiueh, CC, et al. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 1984; 311: 464–467.CrossRefGoogle ScholarPubMed
60. Greenfield, JG, Bosanquet, FD. The brainstem lesion in parkinsonism. J Neurol Neurosurg Psychiatry 1953; 16: 213–226.CrossRefGoogle Scholar
61. Gupta, SK, Murphy, RC, Chandra, SV. Neuro-melanin in manganese-exposed primates. (Letter) Toxicology 1980; 6: 17–20.Google Scholar
62. Lyden, A, Bondesson, U, Larsson, BS, Lindquist, NG. Melanin affinity of l-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, (Letter) Acta Pharmacol Toxicology 1983; 53: 429–432.CrossRefGoogle Scholar
63. Langston, JW Irwin, I, Langston, EB. Parygline prevents MPTP- induced parkinsonism in primates. Science 1984; 225: 1480–1482.CrossRefGoogle Scholar
64. Javitch, JA, D’Amato, RJ, Strittmatter, SM, et al. Parkinsonism-inducing neurotoxin N-methyl-4-phenyl-l,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpiridine by dopamine neurons explains selective toxicity. Proc Nat Acad Sei 1985; 82: 2173–2177.CrossRefGoogle Scholar
65. Burns, RS, LeWitt, PA, Eben, MH, et al. The clinical syndrome of striatal dopamine deficiency-parkinsonism induced by 1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine. N Engl J Med 1985; 312: 1418–1421.CrossRefGoogle Scholar
66. Uhl, GR, Javitch, JA, Snyder, SH. Normal MPTP binding in parkinsonian substantia nigra: evidence for extraneuronal toxic conversion in human brain. Lancet 1985; 1: 956–957.CrossRefGoogle ScholarPubMed
67. Javitch, JA, Snyder, SH. Uptake of MPP by dopamine neurons explains selectivity of parkinsonian-inducing neurotoxin. Eur J Pharm 1985; 10: 455–456.Google Scholar
68. Kopin, IJ. MPTP: an industrial chemical and contaminant of illicit narcotics stimulates a new era in research on Parkinson’s disease. Environ Health Perspec 1987; 75: 45–51.CrossRefGoogle ScholarPubMed
69. Blair, JA, Paween, H, Parford, IA. Aetiology of Parkinson’s disease. Lancet 1984; 1: 167.Google Scholar
70. Leeming, RJ, Pheasant, AE,Blair, JA. The role of tetrahydrobiopterin in neurological disease. J Ment Defic Res 1981; 25: 231–241.Google ScholarPubMed
71. Blair, JA, Pearson, AJ. Non-enzymatic, tetrahydrobiopterin mediated hydroxylation of phenylalanine. J Chem Soc Perk Trans 1975; 11: 245–249.CrossRefGoogle Scholar
72. Forno, LS, Langston, JW, Delanney, LE, et al. Locus ceruleus and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol 1986; 20: 449–455.CrossRefGoogle ScholarPubMed
73. Forno, LS, Langston, JW, Delanney, LE, et al. An electron microscopic study of MPTP-induced inclusion bodies in an old monkey. Brain Res 1988; 448: 150–157.CrossRefGoogle Scholar
74. Davis, KL Yesavage, JA, Berger, PA. Possible organophosophate-induced parkinsonism. J Nerv Ment Dis 1978; 166: 222–225.CrossRefGoogle ScholarPubMed
75. Ohlson, GG, Hogstedt, C. Parkinson’s disease and occupational exposure to organic solvents, agricultural chemicals and mercury — a case-referent study. Scand J Work Environ Health 1981; 7: 252–256.CrossRefGoogle ScholarPubMed
76. Barbeau, A, Roy, M. Genetic susceptibility, environmental factors and Parkinson’s disease. 8th International Symposium on Parkinson’s Disease. New York, June 9–12, 1985.Google Scholar
77. Boccheta, A, Corsini, GU. Parkinson’s disease and pesticides. Lancet 1986; 2: 1163.CrossRefGoogle Scholar
78. Peters, HA, Levine, RL, Matthews, CG, et al. Carbon tetrachloride/-carbon disulfide (80:20 fumigants) and other pesticides in grain storage workers. Acta Pharmacol Toxicol 1986; 59 (Suppl): 535–546.CrossRefGoogle ScholarPubMed
79. Fahn, S. Secondary parkinsonism. In: Goldensohn, ES, Appel, SH, eds. Scientific Approaches to Clinical Neurology. Philadelphia: Lea & Febiger 1977. Vol. 2, 1169–70.Google Scholar
80. Melamed, E, Lavy, S. Parkinsonism associated with chronic inhala- tion of carbon tetrachloride. Lancet 1977; 1: 1015.CrossRefGoogle Scholar
81. Kane, FJ. Carbon disulfide intoxication from overdosage of disulfiram. Am J Psychiatry 1970; 127: 690–694.CrossRefGoogle ScholarPubMed
82. Peters, HA, Gocmen, A, Cripps, DJ, et al. Epidemiology of hexachlorobenzene-induced porphyria in Turkey: clinical and laboratory follow-up after 25 years. Arch Neurol 1982; 39: 744–749.CrossRefGoogle ScholarPubMed
83. Sanchez-Ramos, JR, Hefti, F, Weiner, WJ. Paraquat and Parkinson’s disease. (Letter) Neurology 1987; 37: 728.CrossRefGoogle ScholarPubMed
84. Koller, WC. Paraquat and Parkinson’s disease. (Letter) Neurology 1986; 36: 1147.CrossRefGoogle ScholarPubMed
85. Koller, WC. Paraquat and Parkinson’s disease. (Letter) Neurology 1987; 37: 728.CrossRefGoogle Scholar
86. Carlsson, A, Lindquist, M. In vivo decarboxylation of a-methyl-dopa and a-methylmetatyrosine. Acta Physiol Scand 1962; 54: 87–94.CrossRefGoogle Scholar
87. Groden, BM. Parkinsonism occurring with methyldopa treatment. Br Med J 1963; 1: 1001.CrossRefGoogle ScholarPubMed
88. Peaston, MJT. Parkinsonism associated with alphamethyl dopa therapy. Br Med J 1963; 2: 168.CrossRefGoogle Scholar
89. Strang, RR. Parkinsonism occurring during methyldopa therapy. Can Med Assoc J 1966; 95: 928–929.Google ScholarPubMed
90. Lutz, EG. Neuroleptic-induced parkinsonism facilitated by alcohol. J Med Soc NJ 1978; 76: 473–474.Google Scholar
91. Lutz, EG. Neuroleptic-induced akinisia and dystonia triggered by alcohol. JAMA 1976; 236: 2422.CrossRefGoogle Scholar
92. Carlen, PL, Lee, MA, Jacob, M, et al. Parkinsonism provoked by alcoholism. Ann Neurol 1981; 9: 84–86.CrossRefGoogle ScholarPubMed
93. Lang, AE, Marsden, CD, Obeso, JA, et al. Alcohol and Parkinson disease. Ann Neurol 1982; 12: 254–256.CrossRefGoogle ScholarPubMed
94. Koller, WC. Alcohol and Parkinson disease. Ann Neurol 1983; 13: 467.CrossRefGoogle ScholarPubMed
95. McLean, DR, Jacobs, H, Mielke, BW. Methanol poisoning: a clinical and pathological study. Ann Neurol 1980; 8: 161–167.CrossRefGoogle ScholarPubMed
96. Ley, CO, Gali, FG. Parkinsonian syndrome after methanol intoxication. Eur Neurol 1983; 22: 405–409.Google ScholarPubMed
97. Lutz, EG. Acute lithium-induced parkinsonism precipitated by liquid protein diet. J Med Soc NJ 1978; 75: 165–166.Google ScholarPubMed
98. Ringel, SP, Klawans, HL. Carbon monoxide-induced parkinsonism. J Neurol Sci 1972; 16: 245–251.CrossRefGoogle ScholarPubMed
99. Harris, B, Knapp, MS. Sulfonylurea-induced hypoglycemia associated with unusual neurological features. Diabetes 1968; 17: 522.CrossRefGoogle ScholarPubMed
100. Boranic, M, Raci, F. A parkinson-like syndrome as side effect of chemotherapy with vincristine and adriamycin in a child with acute leukaemia. Biomedicine 1979; 31: 124–125.Google Scholar
101. Bergevin, PR, Patwardhan, VC, Weissman, J, et al. Neurotoxicity of 5-Fluorouracil. Lancet 1975; 1: 410.CrossRefGoogle ScholarPubMed
102. Chermat, R, Simon, P, Boissier, JR. Amoxapine in experimental psycho pharmacology: a neuroleptic or an antidepressant? Arzneim Forsch 1979; 29: 814–820.Google Scholar
103. Charalampous, KD. Amoxapine: a clinical evaluation in depressive syndromes. Curr Ther Res 1972; 14: 657–663.Google ScholarPubMed
104. Steele, JE. Adverse reactions suggesting amoxapine-induced dopamine blockade. Am J Psychiat 1982; 139: 1500–1501.Google ScholarPubMed
105. Thornton, JE, Stahl, SM. Case report of tardive dyskinesia and parkinsonism associated with amoxapine therapy. Am J Psychiat 1984; 141: 704–705.Google ScholarPubMed
106. Lesser, I. Case report of withdrawal dyskinesia associated with amoxapine. Am J Psychiat 1983; 140: 1358–1359.Google ScholarPubMed
107. El-Awar, M, Freedman, M, Seeman, P, et al. Response of tardive and L-dopa-induced dyskinesias to antidepressants. Can J Neuro Sci 1987; 14: 629–631.Google Scholar
108. Strang, RR. Imipramine in treatment of parkinsonism: a double blind placebo study. Br Med J 1965; 5452: 33–34.CrossRefGoogle Scholar
109. Reiderer, P, Reinolds, GP. Deprenyl is a selective inhibitor of brain MOA-B in the long term treatment of Parkinson’s disease. Br J Clin Pharmacol 1980; 9: 98–99.CrossRefGoogle Scholar
110. Teusink, JP, Alexopoulos, GS, Shamoian, CA. Parkinsonian side effects induced by a monamine oxidase inhibitor. Am J Psychiat 1984; 141: 118–119.Google Scholar
111. Weiner, WJ, Nausieda, PA, Klawans, HL. Methylphenidate-induced chorea: case report and pharmacologic implications. Neurology 1978; 28: 1041–1044.CrossRefGoogle ScholarPubMed
112. Casat, CD Wilson, DC. Tics with combined thioridazine-methylphenidate therapy: case report. J Clin Psychiat 1986; 47: 44–45.Google ScholarPubMed
113. Gilman, AG, Goodman, LS, Gilman, A. The pharmacological basis of therapeutics, 6th edition. New York: McMillan 1980; 555.Google Scholar
114. Klawans, HL, Weiner, WJ. The effect of d-amphetamine on choreiform movement disorders. Neurology (Minneap) 1974; 24: 312–318.CrossRefGoogle ScholarPubMed
115. Nausieda, PA, Koller, WC, Weiner, WJ, et al. Chorea induced by oral contraceptives. Neurology 1979; 29: 1605–1609.CrossRefGoogle ScholarPubMed
116. Leys, D, Bourgeois, P, Destee, A, et al. Syndrome choreique et etat psychotique aigns provoques par une substance amphe-taminique. Rev Neurol 1985; 146: 499–500.Google Scholar
117. Gilman, AG, Goodman, LS, Rail, TW, et al. The pharmacological basis of therapeutics, 7th edition. New York: McMillan 1985; 156.Google Scholar
118. Castellani, S. Catatonia associated with phenylpropanoline overdose and fluphenazine treatment: case report. J Clin Psychiat 1985; 46: 288–289.Google ScholarPubMed
119. Ross, RT. Young-age parkinsonism and common drugs. (Letter) Can J Neurol Sci 1989; 16: 366–367.CrossRefGoogle ScholarPubMed
120. Thach, BT, Chase, TN, Bosma, JF. Oral facial dyskinesia associated with prolonged use of antihistamine decongestants. N Engl J Med 1975; 293: 486–487.CrossRefGoogle Scholar
121. Gjerris, F. Transitory procaine-induced parkinsonism. J Neurol Neurosurg Psychiatry 1971; 34: 20–22.CrossRefGoogle ScholarPubMed
122. Gordon, M, Gordon, AS. Perhexiline Maleate as a cause of reversible parkinsonism and peripheral neuropathy. J Am Geriat Soc 1981; 29: 259–262.CrossRefGoogle ScholarPubMed
123. Lervy, B. Parkinson’s disease on treatment with viskaldix. J R Coll Gen Pract 1984; 34: >184.Google ScholarPubMed
124. Lieberman, AN, Goldstein, M. Reversible parkinsonism related to meperidine. N Engl J Med 1985; 8: 509.Google Scholar
125. Fisher, JF, Dewald, J. Parkinsonism associated with intraventricular amphotericin B. J Antimicrob Therap 1983; 12: 97–99.CrossRefGoogle ScholarPubMed
126. Mintz, U, Liberman, UA, Vries, A. Parkinsonism syndrome due to cephaloridine. JAMA 1971; 216: 1200.CrossRefGoogle ScholarPubMed
127. Pearson, DWM, Durward, WF, Fogelman, I, et al. Pseudohypo-parathyroidism presenting as severe parkinsonism. Postgrad Med J 1981; 57: 445–447.CrossRefGoogle Scholar
128. Kataria, M, Traub, M, Marsden, CD. Extrapyramidal side-effects of metoclopramide. Lancet 1978; 2: 1254–1255.CrossRefGoogle ScholarPubMed